Doshi Sahil D, Knezevic Andrea, Gonzalez Carlene, Fischer Patricia, Goodman Robert, Gornell Suzanne, Patel Sweta, Puzio Cindy, Ritea Alisa, Lee Chung-Han, Evans Lauren, Voss Martin H, Motzer Robert J, Kotecha Ritesh R
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Clin Genitourin Cancer. 2025 Feb;23(1):102268. doi: 10.1016/j.clgc.2024.102268. Epub 2024 Nov 13.
Clinical trials enable renal cell carcinoma (RCC) patients to receive promising investigational agents, yet access may be limited. Telemedicine (TM) is an increasingly utilized platform that can expand access, but perspectives on its use in clinical trial care are unknown.
A prospective study was conducted between Jan 2023 - Oct 2023 at Memorial Sloan Kettering Cancer Center. RCC patients enrolled on therapeutic clinical trials who had prior TM visits were eligible. Surveys in English were distributed to patients, treating clinical trial nurses (CTNs), and oncology providers engaged in clinical trials.
39 patients, 7 CTNs, and 15 oncology providers were included in our analysis. Regarding clinical trial care, 26 patients (67%) preferred in-person, 4 (11%) preferred TM, and 9 (22%) had no preference. However, 25 patients (64%) reported TM provided an equal quality of care, and 38 (97%) reported a positive or neutral experience. Conversely, 7 CTNs (100%) and 11 providers (73%) preferred in-person care while 4 (27%) indicated no preference. Most, including 6 CTNs (86%) and 13 providers (87%), reported that TM quality of care was inferior. However, most, including 7 CTNs (100%) and 14 providers (93%), reported a positive experience with TM.
In this study, one third of RCC participants preferred TM or had no preference, and a majority felt TM delivered equal quality of care. Providers, however, preferred in-person visits and reported inferior quality of care with TM. These findings warrant further evaluation of safety and feasibility to optimize TM integration for clinical trial care delivery.
临床试验使肾细胞癌（RCC）患者能够接受有前景的研究药物，但获取途径可能有限。远程医疗（TM）是一个越来越多地被利用的平台，它可以扩大获取途径，但关于其在临床试验护理中的使用观点尚不清楚。
2023年1月至2023年10月在纪念斯隆凯特琳癌症中心进行了一项前瞻性研究。参加过远程医疗就诊的接受治疗性临床试验的肾细胞癌患者符合条件。用英文对患者、治疗临床试验护士（CTN）和参与临床试验的肿瘤学提供者进行了调查。
我们的分析纳入了39名患者、7名CTN和15名肿瘤学提供者。关于临床试验护理，26名患者（67%）更喜欢面对面就诊，4名（11%）更喜欢远程医疗，9名（22%）没有偏好。然而，25名患者（64%）报告远程医疗提供了同等质量的护理，38名（97%）报告有积极或中性的体验。相反，7名CTN（100%）和11名提供者（73%）更喜欢面对面护理，而4名（27%）表示没有偏好。大多数人，包括6名CTN（86%）和13名提供者（87%），报告远程医疗护理质量较差。然而，大多数人，包括7名CTN（100%）和14名提供者（93%），报告有远程医疗的积极体验。
在本研究中，三分之一的肾细胞癌参与者更喜欢远程医疗或没有偏好，并且大多数人认为远程医疗提供了同等质量的护理。然而，提供者更喜欢面对面就诊，并报告远程医疗的护理质量较差。这些发现值得进一步评估安全性和可行性，以优化远程医疗在临床试验护理中的整合。
